Aisling Capital related stories
All articles and analysis
Cidara Therapeutics snags $32 mln Series ABiopharmaceutical firm Cidara Therapeutics said Monday that it has secured $32 million in Series A funding. 5AM Ventures, Aisling Capital, Frazier Healthcare and InterWest Partners were the lead investors. In addition to the financing, the firm has hired Dr. Jeffrey Stein as president and CEO. It has also named Dr. Kevin Judice and Dr. H. Shaw Warren as chief operating officer and chief scientific officer respectively. Warren will also join Cidara's scientific advisory board. And, Dr. Ken Bartizal has been added as chief development officer while Dr. Dirk Thye has joined Cidara as chief medical officer.
- Cidara Therapeutics snags $32 mln Series A
Biopharmaceutical firm Cidara Therapeutics said Monday that it has secured $32 million in Series A funding. 5AM Ventures, Aisling Capital, Frazier Healthcare and InterWest Partners were the lead investors. In addition to the financing, the firm has hired Dr. Jeffrey Stein as president and CEO. It has also named Dr. Kevin Judice and Dr. H. Shaw Warren as chief operating officer and chief scientific officer respectively. Warren will also join Cidara's scientific advisory board. And, Dr. Ken Bartizal has been added as chief development officer while Dr. Dirk Thye has joined Cidara as chief medical officer.
Strong gains boost INPRS’ venture portfolio:VCJThe Indiana Public Retirement System’s recent-vintage venture-capital portfolio notched strong gains in the second half of last year, affiliate magazine Venture Capital Journal reported.
Fund performance: Strong gains boost INPRS’ venture portfolioLate decade funds from Trinity, IVP, DCM advanced smartly
- PowerVision rakes in $30 mln Series D
PowerVision has closed $30 million in Series D funding. The investors included Aisling Capital, Correlation Venture Partners and Venrock. Based in Belmont, Calif., PowerVision is developing an intraocular lens.
- PowerVision rakes in $30 mln Series D
PowerVision has closed $30 million in Series D funding. The investors included Aisling Capital, Correlation Venture Partners and Venrock. Based in Belmont, Calif., PowerVision is developing an intraocular lens.
- IPO Profile: Agile Therapeutics Inc
Aisling Capital, Care Capital, Kaiser Permanente Ventures and others invested about $92 million in the company and saw a total return of 1.02x at the IPO price
- VC-backed Agile Therapeutics rolls out IPO
Agile Therapeutics has launched its IPO after pricing its over 9.16 million shares at $6 per share. The stock began trading Friday on the NASDAQ under the ticker symbol "AGRX." RBC Capital Markets and William Blair & Company are the lead underwriters. Based in Princeton, NJ, Agile Therapeutics develops prescription contraceptives. Its backers include Aisling Capital, Care Capital, Investor Growth Capital, ProQuest Investments, Kaiser Permanente Ventures and Novitas Capital.
- NEA leads Series B round for Loxo Oncology
Loxo Oncology has received $24 million in Series B financing. New Enterprise Associates led the round with participation from previous backers Aisling Capital and OrbiMed Advisors. In addition to the funding, Dr. M. James Barrett, a general partner at NEA, will join Loxo Oncology's board of directors while Dr. Sara Nayeem, a principal at NEA, will also join the board as an observer. And, the firm has named Dr. Mikel Moyer as chief scientific officer. Loxo Oncology is a a biopharmaceutical company focused on targeted cancer therapies.
- IPO Profile: Versartis Inc
Advent Life Sciences, Aisling Capital, Amunix, Fidelity, Index Ventures, New Leaf Ventures and Sofinnova Venture Partners own 14,770,487 shares worth about $310 million at the IPO price.